Amniotic stem cell transplantation therapy for type 2 diabetes: 3 years’ follow-up report

Y. Liu, L.-B. Guo, J.-K. Xu

Department of Stem Cell Clinical Application Center, Siping Hospital of China Medical University, Siping, Jilin, China. ly3641829@163.com

---

• Metabolism

OBJECTIVE: These case series present a retrospective analysis of clinical effects that an allogeneic amniotic cell transplantation can have in treating 4 patients with type 2 diabetes.

PATIENTS AND METHODS: Eligible diabetic patients were onset within 3 years, with fasting blood glucose > 7.0 mmol/l. Stem – cells that are collected from neonatal amniotic membrane when a child is born (2 x 107 cells) – are used for the treatment of these patients. Measured by the flow cytometry, stem cells transfer clusters of differentiation CD113 and CD34 at a high level, and through the femoral artery on the left, they are administered into the patient’s pancreatic dorsal artery.

RESULTS: The major outcome of the study is the improvement of glycemic control. After withdrawing insulin completely, 13.2 months later, there is a reincrease in the level of blood glucose of the patient. After adjusting their treatment again, no one required using insulin again; only need metformin (250-500 mg/day) to control blood glucose levels.

CONCLUSIONS: Since this therapy showed no effects on C-peptide, our results suggested one plausible therapeutic strategy improving glycemic control by increasing insulin sensitivity.

Free PDF Download